J. Dunn

A. Marshall, J. Dunn, B. Naidu, 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Genome-wide association study of germline variants and breast cancer-speci ﬁ c mortality

A. Whittemore, M. Beckmann, A. Talhouk, 2019 .

SELECT-D: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism.

A. Marshall, J. Dunn, A. Young, 2014 .

Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism : results of the 'select-d' Pilot Trial

A. Marshall, J. Dunn, M. Levine, 2018 .

Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D™ Pilot Trial

A. Marshall, J. Dunn, M. Levine, 2017 .

Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D Trial (SELECT‐D: 12m)

F. Hobbs, A. Maraveyas, A. Marshall, 2020, Journal of thrombosis and haemostasis : JTH.

Management of Advanced Head and Neck Cancer.

W. Wong, J. Dunn, H. Mehanna, 2016, The New England journal of medicine.

Thoracoscore fails to predict complications following elective lung resection

A. Marshall, J. Dunn, K. Hussain, 2012, European Respiratory Journal.

Neo-escape: Neoadjuvant extended sequential chemotherapy with adjuvant postoperative treatment for epithelial nonmucinous advanced inoperable peritoneal malignancy.

C. Poole, A. Marshall, J. Dunn, 2012 .

University of Birmingham Changing case Order to Optimise patterns of Performance in mammography Screening (CO-OPS)

M. Wallis, S. Taylor-Phillips, S. Gates, 2014 .

Cabazitaxel in Platinum Pre-treated Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression after Platinum based Chemotherapy: Results of the Phase II CAB-B1 Trial

N. James, A. Zarkar, A. Marshall, 2019, International Journal of Cancer Research & Therapy.

Radical treatment of muscle-invasive bladder cancer—are options equal?

A. Zarkar, A. Marshall, J. Dunn, 2018, Journal of Radiation Oncology.

Synchronous versus sequential chemoradiotherapy in patients with early stage breast cancer (SECRAB)

D. Rea, C. Poole, I. Ahmed, 2020 .

COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.

D. Cunningham, J. Bridgewater, S. Madhusudan, 2013 .

PHASE III RANDOMISED COMPARISON OF GEMCITABINE (GEM) WITH GEMCITABINE PLUS CAPECITABINE (GEM-CAP) IN PATIENTS WITH ADVANCED PANCREATIC CANCER

J. Neoptolemos, D. Stocken, J. Dunn, 2005 .

ESPAC-1: A European, randomised study to assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer

D. Kerr, J. Neoptolemos, C. Bassi, 2001 .

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. Dziewulski, M. Gore, M. Highley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessing violations of the proportional hazards assumption in Cox regression: does the chosen method matter?

A. Marshall, J. Dunn, L. Hiller, 2015, Trials.

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

C. R. Leemans, C. McConkey, T. Roques, 2019, The Lancet.

Improvement in Dysphagia Outcomes Following Clinical Target Volume Reduction in the De-ESCALaTE Study.

T. Roques, J. Dunn, H. Mehanna, 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial

J. Dunn, H. Mehanna, P. Sanghera, 2020, Oral Oncology.

Low serum 25-hydroxyvitamin D is associated with increased bladder cancer risk: A systematic review and evidence of a potential mechanism

J. Dunn, R. Bland, K. Jefferson, 2019, The Journal of Steroid Biochemistry and Molecular Biology.

MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRC Working Party on Leukaemia in Adults.

M. Drayson, I. Maclennan, J. Dunn, 1998, British journal of haematology.

Follow-up in early breast cancer--a surgical and radiological perceptive.

M. Wilcox, A. Marshall, J. Dunn, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

Commentary on: Introduction of an abbreviated breast MRI service in the UK as part of the BRAID trial: practicalities, challenges, and future directions.

J. Dunn, L. Jones, 2021, Clinical radiology.

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials

G. Morgan, W. Gregory, M. Drayson, 2022, Blood advances.

Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial

M. Drayson, E. Low, J. Dunn, 2020, British journal of haematology.

Rapid diagnostic service for patients with haematuria.

J. Dunn, D. Wallace, T. Lynch, 1994, British journal of urology.

Prognostic factors in acute renal failure following aortic aneurysm surgery.

D. Adu, R. McGonigle, J. Dunn, 1990, The Quarterly journal of medicine.

Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder.

J. Dunn, D. Raghavan, D. Wallace, 1991, British journal of urology.

Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone.

A. Padhani, D. Koh, A. Makris, 2020, Radiology.

Genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

Sara M. Willems, Audrey Y. Chu, Daniel F. Freitag, 2016 .

Etoposide protein binding in cancer patients

D. Kerr, H. Earl, C. Poole, 2004, Cancer Chemotherapy and Pharmacology.

Qualitative and quantitative analysis of peritoneal fluids from women with gynecologic diseases. Comparison of cytology and flow cytometry for the detection of malignancy in lavage and ascitic fluids.

C. Redman, J. Dunn, D. Luesley, 1991, Analytical and quantitative cytology and histology.

Delay and survival in bladder cancer

J. Dunn, R. Bryan, S. Bathers, 2002, BJU international.

The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up

W. Allum, J. Dunn, M. Hallissey, 1994, The Lancet.

Common germline polymorphisms associated with breast cancer-specific survival

W. Willett, S. Cross, M. Beckmann, 2015, Breast Cancer Research.

Genome-wide association study of germline variants and breast cancer-specific mortality

A. Whittemore, W. Willett, S. Cross, 2019, British Journal of Cancer.

ARTemis: Randomized trial with neoadjuvant chemotherapy for patients with early breast cancer.

C. Caldas, H. Earl, J. Bartlett, 2012 .

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

D. Kerr, H. Friess, J. Neoptolemos, 2001, The Lancet.

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

N. Dhomen, R. Marais, P. Lorigan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.

C. Caldas, E. Provenzano, S. Dawson, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

L. Esserman, S. Edge, L. Pusztai, 2021, The Lancet. Oncology.

Effect of Using the Same vs Different Order for Second Readings of Screening Mammograms on Rates of Breast Cancer Detection: A Randomized Clinical Trial.

Aileen Clarke, Nigel Stallard, Sian Taylor-Phillips, 2016, JAMA.

PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck ca

B. Sanghera, C. McConkey, W. Wong, 2017, Health technology assessment.

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Helen Hickey, Helmut Friess, François Lacaine, 2004, The New England journal of medicine.

Advanced head and neck cancer: is there a role for fluorodeoxyglucose PET/computed tomography?

K. Maclennan, W. Wong, C. Nutting, 2009, Nuclear medicine communications.

Multi-omic machine learning predictor of breast cancer therapy response

F. Markowetz, S. Chin, C. Caldas, 2021, Nature.

Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases.

J. Dunn, M. Brada, T. Priestman, 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer.

D. Levison, J. Dunn, M. Demonakou, 1995, British Journal of Cancer.

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

Mike Clarke, K Wheatley, A Riccardi, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy in pancreatic cancer: historical and current perspectives.

H. Friess, M. Büchler, D. Tait, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A qualitative systematic review exploring lay understanding of cancer by adults without a cancer diagnosis.

F. Griffiths, J. Dunn, C. Balmer, 2014, Journal of advanced nursing.

Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis

I. Maclennan, J. Dunn, C. Chapman, 1992, The Lancet.

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.

W. Scheithauer, C. Tudur-Smith, R. Herrmann, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer.

C. McConkey, W. Wong, C. Nutting, 2016, The New England journal of medicine.

Influence of Surgical Resection and Post-Operative Complications on Survival following Adjuvant Treatment for Pancreatic Cancer in the ESPAC-1 Randomized Controlled Trial

H. Friess, M. Büchler, J. Neoptolemos, 2006, Digestive Surgery.

A review of the issues and challenges involved in using participant-produced photographs in nursing research.

F. Griffiths, J. Dunn, C. Balmer, 2015, Journal of advanced nursing.

Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population

R. Hobbs, M. Wakelam, T. Ismail, 2006 .

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

H. Earl, D. Rea, S. M. Crawford, 2006, The New England journal of medicine.

Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party.

G. Morgan, M. Drayson, F. Davies, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Considerations for a head and neck smoking cessation support programme; A qualitative study of the challenges in quitting smoking after treatment for head and neck cancer.

J. Dunn, H. Mehanna, C. Balmer, 2018, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Abnormal cervical cytology following large loop excision of the transformation zone: a case controlled study.

J. Dunn, M. Shafi, D. Luesley, 1993, British journal of obstetrics and gynaecology.

Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials.

M. Drayson, S. Basu, J. Dunn, 2006, Blood.

Current Issues in Cancer: Multiple myeloma

M. Drayson, I. Maclennan, J. Dunn, 1994 .

Multiple myeloma.

M. Drayson, I. Maclennan, J. Dunn, 1994, BMJ.

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.

R. Laing, C. Caldas, E. Provenzano, 2014, The Lancet. Oncology.

Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myeloma

J. Kanis, E. McCloskey, M. Drayson, 2001, British journal of haematology.

Impact of adjuvant chemotherapy in breast cancer on response to tamoxifen at relapse.

D. Kerr, J. Dunn, J. M. Morrison, 1993, Cancer treatment reviews.

Prospective Randomized Comparison of Dacarbazine (DTIC) Versus DTIC Plus Interferon-Alpha (IFN-α) in Metastatic Melanoma

J. Dunn, J. Marsden, A. Burton, 2001 .

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

C. Caldas, E. Provenzano, H. Earl, 2010, The Lancet. Oncology.

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

M. Gore, P. Nathan, P. Lorigan, 2014, The Lancet. Oncology.

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.

C. Caldas, J. Abraham, H. Earl, 2018 .

Adaptive designs for clinical trials assessing biomarker-guided treatment strategies

N Stallard, A Marshall, J. Wason, 2014, British Journal of Cancer.

Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.

J. Donovan, S. Pinder, H. Earl, 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training

John M S Bartlett, Robert C Stein, Tammy Piper, 2020, PloS one.

Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.

C. Caldas, E. Provenzano, J. Abraham, 2020, Health technology assessment.

The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation

E. Provenzano, H. Earl, D. Rea, 2019, Journal of clinical epidemiology.

Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial.

H. Earl, D. Rea, A. Makris, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study

P. Boutros, G. Pond, D. Rea, 2021, NPJ breast cancer.

A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer.

N. James, J. Catto, J. Dunn, 2015, European urology focus.

Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial

A. Gray, J. Dunn, A. Kong, 2019, European journal of cancer.

Adjuvante und additive Therapie beim Pankreaskarzinom

H. Friess, D. Stocken, P. Ghaneh, 2003, Der Chirurg.

A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix.

J. Herod, C. Poole, J. Dunn, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Socio‐economic deprivation and survival in bladder cancer

J. Dunn, R. Bryan, D M Wallace, 2004, BJU international.

Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean?

Elena Provenzano, Janet Dunn, E. Provenzano, 2015, BMC Medicine.

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials

G. Morgan, W. Gregory, M. Drayson, 2018, Leukemia.

Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean?

E. Provenzano, J. Abraham, H. Earl, 2015, BMC Medicine.

tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC)

Janet A. Dunn, Helen Howard, Helena M. Earl, 2008 .

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

M. Drayson, E. Low, J. Dunn, 2019, The Lancet. Oncology.

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

D. Cunningham, J. Bridgewater, S. Madhusudan, 2014, The Lancet. Oncology.

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis

Gary D Bader, S. Cross, M. Beckmann, 2020, Nature Communications.

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis

Gary D. Bader, Christine L. Clarke, Gary D Bader, 2020, Nature Communications.

[Adjuvant and additive therapy for cancer of the pancreas].

H. Friess, J. Neoptolemos, D. Stocken, 2003, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

OP025: Epidemiology of human papilloma virus associated oropharyngeal cancer in England and Wales: Recent UK estimates in the last decade from the (PET-NECK) randomised controlled trial

P. Sasieni, J. Dunn, H. Mehanna, 2013 .

LIHNCS (Lugol's Iodine in Head and Neck Cancer Surgery): a UK Multicentre Prospective Randomised Controlled Trial. Report of primary and secondary outcome measures

R. Shaw, J. Dunn, J. McCaul, 2015 .

Can mammogram readers swiftly and effectively learn to interpret first post-contrast acquisition subtracted (FAST) MRI, a type of abbreviated breast MRI?: a single centre data-interpretation study.

S. Taylor-Phillips, A. Marshall, J. Dunn, 2019, The British journal of radiology.

OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism.

A. Marshall, J. Dunn, A. Young, 2016, Thrombosis research.

Options for early breast cancer follow-up in primary and secondary care - a systematic review

J. Dunn, F. Taggart, P. Donnelly, 2012, BMC Cancer.

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT.

M. Drayson, E. Low, J. Dunn, 2019, Health technology assessment.

Cigarette Smoking and Histological Outcome in Women With Mildly Dyskaryotic Cervical Smears

J. Dunn, R. Chenoy, M. Shafi, 1994 .

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

D. Kerr, C. McConkey, J. Dunn, 2007, The New England journal of medicine.

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial

C. Caldas, E. Provenzano, J. Abraham, 2013, British Journal of Cancer.

Pregnancy outcome after large loop excision of the cervical transformation zone.

J. Dunn, D. Luesley, J. Buxton, 1993, American journal of obstetrics and gynecology.

Lesion size and histology of atypical cervical transformation zone

J. Dunn, M. Shafi, J. Jordan, 1991, British journal of obstetrics and gynaecology.

Abnormal cervical cytology following large loop excision of the transformation zone: a case controlled study

J. Dunn, M. Shafi, D. Luesley, 1993 .

The Value of Source Data Verification in a Cancer Clinical Trial

Catrin Tudur Smith, John P. Neoptolemos, Janet Dunn, 2012, PloS one.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

C. Caldas, E. Provenzano, J. Abraham, 2019, The Lancet.

versus 12 months of adjuvant trastuzumab for HER 2-positive early breast cancer ( PERSEPHONE ) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

C. Caldas, E. Provenzano, J. Abraham, 2019 .

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

H. Earl, D. Miles, D. Cameron, 2018, BMC Cancer.

Trastuzumab-associated cardiac events in the Persephone trial

J. Abraham, H. Earl, D. Miles, 2016, British Journal of Cancer.

Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial

C. Caldas, E. Provenzano, J. Abraham, 2017, Modern Pathology.

Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.

D. Kerr, C. McConkey, B. Warren, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long–Term Risk of Salvage Cystectomy after Radiotherapy for Muscle–Invasive Bladder Cancer

P. Cooke, N. James, J. Dunn, 2000, European Urology.

LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer

J. Abraham, H. Earl, H. Joensuu, 2021, Annals of Oncology.

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial

N. A. Walton, M. J. Irwin, J. D. Brenton, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Involving patients in clinical trial design : the experience of the UK Ibreast early breast cancer follow-up trial

M. Wilcox, J. Austoker, J. Dunn, 2009 .

A ‘new normal’: Exploring the disruption of a poor prognostic cancer diagnosis using interviews and participant-produced photographs

F. Griffiths, J. Dunn, C. Balmer, 2015, Health.

Modelling the cost-effectiveness of first, second and third generation polychemotherapy regimens in women with early breast cancer who have differing prognoses.

M. Sculpher, H. Earl, J. Yarnold, 2009 .

Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence from the UK NEA Tadjuvant breast cancer trial

C. Caldas, E. Provenzano, H. Earl, 2009 .

Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients

M. Drayson, J. Dunn, T. Planche, 2017 .

FKBPL: a marker of good prognosis in breast cancer

I. Ellis, A. Green, E. Rakha, 2015, Oncotarget.

Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.

G. Morgan, M. Dimopoulos, M. Drayson, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Changing case Order to Optimise patterns of Performance in mammography Screening (CO-OPS): study protocol for a randomized controlled trial

M. Wallis, S. Taylor-Phillips, A. Clarke, 2014, Trials.

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

H. Earl, D. Miles, A. Wardley, 2018, BMC Cancer.

A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients

A. Carmichael, A. Marshall, J. Dunn, 2020, Breast Cancer Research and Treatment.

Duplication of Chromosome 17 CEP Predicts for Anthracycline Benefit: A Meta-Analysis of 4 Trials.

C. Desmedt, D. Larsimont, C. Caldas, 2009 .

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

C. Caldas, J. Abraham, H. Earl, 2020, Clinics in oncology.

National randomised controlled trial is needed

J. Dunn, L. Hiller, P. Donnelly, 2008, BMJ : British Medical Journal.

Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer

D. Kerr, J. Dunn, J. Fielding, 1999, British Journal of Cancer.

Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data

S. Park, A. Marshall, J. Dunn, 2016, British Journal of Cancer.

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results.

H. Earl, J. Dunn, P. Hall, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective randomized trial to evaluate different oral dose regimens of medroxyprogesterone acetate in women with advanced breast cancer.

J. Dunn, H. Earl, T. Priestman, 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

Feasibility of recruitment to an oral dysplasia trial in the United Kingdom

J. Dunn, H. Mehanna, M. Langman, 2012, Head & neck oncology.

An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment

R. Peto, J. Donovan, T. Powles, 2018, Journal of clinical epidemiology.

Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open‐label, single‐arm, phase 2 study (ISRCTN34303497)

F. Khanim, C. Bunce, M. Drayson, 2014, British journal of haematology.

Management of advanced nodal disease in patients treated with primary chemoradiotherapy

W. Wong, J. Dunn, H. Mehanna, 2016, Current opinion in oncology.

Consolidated criteria for reporting qualitative research guidelines

J. Donovan, S. Pinder, A. Makris, 2016 .

MRC trial of α2b‐interferon maintenance therapy in first plateau phase of multiple myeloma

M. Drayson, I. Maclennan, J. Dunn, 1998 .

The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial

A. Marshall, J. Dunn, C. Hulme, 2015, PharmacoEconomics.

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

C. Caldas, E. Provenzano, H. Earl, 2012, British Journal of Cancer.

Explorer Adjuvant epirubicin followed by cyclophosphamide , methotrexate and fluorouracil ( CMF ) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT / BR 9601 trials

C. Caldas, E. Provenzano, P. Pharoah, 2018 .

Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management

M. Drayson, J. Heaney, J. Dunn, 2020, Blood Cancer Journal.

Progress by Collaboration: ESPAC Studies

H. Friess, M. Büchler, J. Neoptolemos, 2004 .

Survival from relapse and the influence of therapy

G. Morgan, M. Drayson, F. Davies, 2007 .

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial

M. Drayson, K. Ramasamy, Sherin Varghese, 2022, Blood Cancer Journal.

A prospective study to assess the value of MMP-9 in improving the appropriateness of urgent referrals for colorectal cancer

R. Hobbs, M. Wakelam, T. Ismail, 2006, BMC Cancer.

Abstract PD2-3: ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer

C. Caldas, E. Provenzano, J. Abraham, 2015 .

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.

M. Gore, P. Nathan, P. Lorigan, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cougar-02 : a randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma

D. Cunningham, J. Bridgewater, S. Madhusudan, 2013 .

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial

P. Lorigan, A. Marshall, J. Dunn, 2018, British Journal of Cancer.

Radiation Therapy Variation in the Randomized Phase 3 Positron Emission Tomography Neck Study

C. McConkey, W. Wong, C. Nutting, 2016 .

Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma

J. Dunn, H. Gee, K. Oláh, 1992 .

Abstract P4-11-07: Comparison of multiparameter tests in the UK OPTIMA-Prelim trial

J. Donovan, S. Pinder, A. Makris, 2015 .

Abstract P6-08-11: UK OPTIMA-prelim study demonstrates economic value in more clinical evaluation of multi-parameter prognostic tests in early breast cancer

J. Donovan, S. Pinder, H. Earl, 2015 .

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub‐types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial

Carlos Caldas, Elena Provenzano, C. Caldas, 2013, International journal of cancer.

C. Caldas, E. Provenzano, J. Abraham, 2015, The Lancet. Oncology.

PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer.

C. McConkey, W. Wong, C. Nutting, 2016, The New England journal of medicine.

LIHNCS; randomised control trial in oral and maxillofacial surgery interim data and recruitment report

R. Shaw, C. McConkey, J. Dunn, 2012 .

The MRC randomised trial of the use of α2b-interferon in first plateau phase in multiple myeloma

M. Drayson, I. Maclennan, J. Dunn, 1998 .

Observer variability among colposcopists from the West Midlands region

J. Dunn, M. Shafi, J. Jordan, 1997, British Journal of Obstetrics and Gynaecology.

34. Pathological and immunohistochemical prognostic factors in clinically node-negative breast cancer patients receiving adjuvant tamoxifen (BR3002 trial)

S. Parnell, J. Dunn, G. Oates, 1995 .

The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study

C. Caldas, J. Abraham, H. Earl, 2016, PloS one.

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

G. Lyman, F. Hobbs, A. Maraveyas, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.

G. Morgan, M. Dimopoulos, M. Drayson, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Follow-Up After Breast Cancer

J. Dunn, L. Hiller, P. Donnelly, 2019, Breast Diseases.

Genome-wide association study of germline variants and breast cancer-specific mortality

A. Whittemore, W. Willett, S. Cross, 2019, British Journal of Cancer.

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

D. Cunningham, J. Bridgewater, S. Madhusudan, 2014, The Lancet. Oncology.

Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V Trial

I. Maclennan, J. Dunn, R. Brown, 1993, British journal of haematology.

Options for early breast cancer follow-up in primary and secondary care - a systematic review

J. Dunn, F. Taggart, P. Donnelly, 2012, BMC Cancer.

Effect of Using the Same vs Different Order for Second Readings of Screening Mammograms on Rates of Breast Cancer Detection: A Randomized Clinical Trial.

M. Wallis, V. Adekanmbi, S. Taylor-Phillips, 2016, JAMA.

Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy.

A. Gray, J. Buter, J. Dunn, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study

M. Drayson, E. Low, J. Heaney, 2020 .

Optima: Optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test-directed chemotherapy treatment in a largely node-positive population.

B. Kiely, D. Rea, B. Naume, 2021 .

OPTIMA (Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.

S. Pinder, H. Earl, D. Rea, 2016 .

FKBPL: a marker of good prognosis in breast cancer

I. Ellis, E. Rakha, J. Bartlett, 2015, Oncotarget.

Abstract GS4-07: Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, residual cancer burden class and neo-bioscore

L. Esserman, L. Pusztai, C. Caldas, 2021 .

ARTemis: A randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer-Primary endpoint, pathological complete response (pCR)

C. Caldas, E. Provenzano, J. Abraham, 2014 .